{"id":"omega-3-carboxylic-acids","rwe":[{"pmid":"40731220","year":"2025","title":"The omega effect: Harnessing fish oil for health.","finding":"","journal":"Atherosclerosis","studyType":"Clinical Study"},{"pmid":"36719059","year":"2023","title":"PNPLA3 I148M and response to treatment for hepatic steatosis: A systematic review.","finding":"","journal":"Liver international : official journal of the International Association for the Study of the Liver","studyType":"Clinical Study"},{"pmid":"34618982","year":"2021","title":"Omega-3 carboxylic acids and fenofibrate differentially alter plasma lipid mediators in patients with non-alcoholic fatty liver disease.","finding":"","journal":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","studyType":"Clinical Study"},{"pmid":"34431129","year":"2021","title":"Omega-3 fatty acids for the prevention of atherosclerotic cardiovascular disease.","finding":"","journal":"Pharmacotherapy","studyType":"Clinical Study"},{"pmid":"33392871","year":"2021","title":"Highlights from Studies Presented at the American Heart Association Scientific Session 2020: Navigating New Roads in Prevention.","finding":"","journal":"Current atherosclerosis reports","studyType":"Clinical Study"}],"tags":[{"label":"Omega-3 Fatty Acid","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"LOE Approaching","category":"status"},{"label":"Hypertriglyceridemia","category":"indication"},{"label":"Astrazeneca","category":"company"},{"label":"Approved 2010s","category":"decade"}],"phase":"marketed","safety":{},"trials":[],"aliases":[],"company":"AstraZeneca","patents":[{"applNo":"N205060","source":"FDA Orange Book","status":"Active","expires":"Jan 4, 2033","useCode":"U-2447","territory":"US","drugProduct":false,"patentNumber":"10117844","drugSubstance":false},{"applNo":"N205060","source":"FDA Orange Book","status":"Active","expires":"Jan 4, 2033","useCode":"U-1511","territory":"US","drugProduct":false,"patentNumber":"9050308","drugSubstance":false},{"applNo":"N205060","source":"FDA Orange Book","status":"Active","expires":"Jan 4, 2033","useCode":"","territory":"US","drugProduct":false,"patentNumber":"9050309","drugSubstance":true},{"applNo":"N205060","source":"FDA Orange Book","status":"Active","expires":"Dec 20, 2026","useCode":"","territory":"US","drugProduct":true,"patentNumber":"7960370","drugSubstance":false}],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=OMEGA-3-CARBOXYLIC ACIDS","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:09:56.360318+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-20T00:09:56.358415+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Omega-3-Carboxylic Acids","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T00:10:03.547172+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:10:01.685438+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=OMEGA-3-CARBOXYLIC ACIDS","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:10:02.004000+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3137327/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:10:03.209970+00:00"}},"allNames":"epanova","offLabel":[],"synonyms":["omega-3-carboxylic acids","omega-3 carboxylic acid","epanova","long chain omega-3 and omega-6 fatty acids"],"timeline":[{"date":"2014-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from ASTRAZENECA PHARMS to Astrazeneca"},{"date":"2014-05-05","type":"positive","source":"DrugCentral","milestone":"FDA approval (Astrazeneca Pharms)"},{"date":"2033-01-04","type":"negative","source":"FDA Orange Book","milestone":"Substance patent 9050309 expires"}],"approvals":[{"date":"2014-05-05","orphan":false,"company":"ASTRAZENECA PHARMS","regulator":"FDA"}],"brandName":"Epanova","ecosystem":[{"indication":"Hypertriglyceridemia","otherDrugs":[{"name":"atorvastatin","slug":"atorvastatin","company":"Pfizer"},{"name":"choline fenofibrate","slug":"choline-fenofibrate","company":"Abbvie"},{"name":"fenofibrate","slug":"fenofibrate","company":"Abbvie"},{"name":"gemfibrozil","slug":"gemfibrozil","company":"Pfizer Pharms"}],"globalPrevalence":1680000000}],"mechanism":{"modality":"Small Molecule","drugClass":"Omega-3 Fatty Acid","explanation":"","oneSentence":"","technicalDetail":"Epanova, a mixture of omega-3 carboxylic acids, is thought to exert its effects through the inhibition of diacylglycerol acyltransferase 1 (DGAT1), an enzyme involved in triglyceride synthesis in the liver."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Omega-3-carboxylic_acids","title":"Omega-3-carboxylic acids","extract":"Omega−3-carboxylic acids (Epanova) is a formerly marketed yet still not a Food and Drug Administration (FDA)-approved prescription medication–since taken off market by the manufacturer–used alongside a low fat and low cholesterol diet that lowers high triglyceride (fat) levels in adults with very high levels. This was the third class of fish oil-based drug, after omega−3-acid ethyl esters and ethyl eicosapentaenoic acid (Vascepa), to be approved for use as a drug. The first approval in the United States by the FDA was granted 05 May 2014. These fish oil drugs are similar to fish oil dietary supplements, but the ingredients are better controlled and have been tested in clinical trials. Specifically, Epanova contained at least 850 mg omega−3-acid ethyl esters per 1 g capsule."},"commercial":{"launchDate":"2014","_launchSource":"DrugCentral (FDA 2014-05-05, ASTRAZENECA PHARMS)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/5126","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=OMEGA-3-CARBOXYLIC%20ACIDS","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=OMEGA-3-CARBOXYLIC ACIDS","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Omega-3-carboxylic_acids","fields":["history","overview"],"source":"Wikipedia"},{"id":5,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T15:10:24.979892","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:10:05.091255+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[],"genericName":"omega-3-carboxylic acids","indications":{"approved":[{"name":"Hypertriglyceridemia","source":"DrugCentral","snomedId":302870006,"regulator":"FDA","usPrevalence":null,"globalPrevalence":1680000000,"prevalenceMethod":"curated","prevalenceSource":"J Health Popul Nutr, 2025 (PMID:40859400)"}],"offLabel":[],"pipeline":[]},"currentOwner":"Astrazeneca","drugCategory":"loe-approaching","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT07399743","phase":"PHASE3","title":"Effects of Lower Body Positive Pressure Therapy Versus Alpha Lipoic Acid and Omega-3 Fatty Acids on Knee Osteoarthritis","status":"NOT_YET_RECRUITING","sponsor":"Badr University","startDate":"2026-02-15","conditions":["Knee Osteoarthritis"],"enrollment":160,"completionDate":"2026-07-01"},{"nctId":"NCT02330926","phase":"PHASE3","title":"Multimodal Intervention for Cachexia in Advanced Cancer Patients Undergoing Chemotherapy","status":"COMPLETED","sponsor":"Norwegian University of Science and Technology","startDate":"2015-04","conditions":["Cachexia","Neoplasms"],"enrollment":221,"completionDate":"2023-04"},{"nctId":"NCT06995586","phase":"NA","title":"Dietary Supplements in Patients With Coronary Artery Bypass Grafting for Improving the Quality of Healthcare Delivery.","status":"NOT_YET_RECRUITING","sponsor":"Nicosia General Hospital","startDate":"2025-09-01","conditions":["Cardio-pulmonary Bypass","Cardiovascular Diseases","Omega-3 Polyunsaturated Fatty Acids","Omega-3 Supplementation","Vitamin C","Supplements","Postoperative Depression","Antioxidants","Lactulose","Postoperative","Optimal Medical Therapy","CABG","Coronary Artery Bypass Grafting","Prebiotics"],"enrollment":108,"completionDate":"2028-09-01"},{"nctId":"NCT03110432","phase":"","title":"Prospective German Very High Cardiovascular Risk Patients Dyslipidemia Treatment Indication Registry","status":"COMPLETED","sponsor":"GWT-TUD GmbH","startDate":"2017-05-18","conditions":["Dyslipoproteinemias","Hypercholesterolemia, Familial","Familial Hypercholesterolemia - Homozygous","Familial Combined Hyperlipidemia"],"enrollment":1695,"completionDate":"2024-04-17"},{"nctId":"NCT05281562","phase":"PHASE2,PHASE3","title":"Immunonutrition for Diabetic Foot Ulcers","status":"TERMINATED","sponsor":"Prisma Health-Midlands","startDate":"2023-02-08","conditions":["Diabetes Mellitus","Diabetic Peripheral Neuropathy","Diabetic Foot Ulcer"],"enrollment":1,"completionDate":"2023-03-20"},{"nctId":"NCT06190132","phase":"NA","title":"The Effect of Omega-3 Fatty Acids Versus Gabapentin in Uremic Pruritus in Hemodialysis Patients","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2023-04-01","conditions":["Uremic Pruritus in Hemodialysis Patients"],"enrollment":50,"completionDate":"2023-07-30"},{"nctId":"NCT03510884","phase":"PHASE3","title":"An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-05-31","conditions":["Hypercholesterolaemia"],"enrollment":153,"completionDate":"2022-08-05"},{"nctId":"NCT04828538","phase":"NA","title":"Vitamin D, Omega-3, and Combination Vitamins B, C and Zinc Supplementation for the Treatment and Prevention of COVID-19","status":"WITHDRAWN","sponsor":"Hospital de la Soledad","startDate":"2021-01-01","conditions":["Covid19"],"enrollment":0,"completionDate":"2021-12-31"},{"nctId":"NCT05527106","phase":"NA","title":"Evaluation of the Effect of Citicoline and Docosahexaenoic Acid (DHA) on the Visual Function of Patients With Glaucoma","status":"COMPLETED","sponsor":"Institut Catala de Retina","startDate":"2015-03-12","conditions":["Glaucoma"],"enrollment":73,"completionDate":"2022-05-25"},{"nctId":"NCT04006847","phase":"PHASE1,PHASE2","title":"Omega -3 Fatty Acid in Combination With Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia","status":"TERMINATED","sponsor":"Milton S. Hershey Medical Center","startDate":"2020-09-14","conditions":["Chronic Myeloid Leukemia, Chronic Phase"],"enrollment":1,"completionDate":"2021-05-21"},{"nctId":"NCT02104817","phase":"PHASE3","title":"Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-10-30","conditions":["Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD)"],"enrollment":13078,"completionDate":"2020-05-27"},{"nctId":"NCT04907864","phase":"PHASE2","title":"Effect of Multi-modal Intervention Care on Cachexia in Patients With Advanced Cancer Compared to Conventional Management (MIRACLE)","status":"UNKNOWN","sponsor":"Kil Yeon Lee","startDate":"2020-01-31","conditions":["Gastric Cancer","Colorectal Cancer","Pancreatic Cancer","Biliary Tract Cancer","Lung Cancer","Precachexia","Cachexia"],"enrollment":112,"completionDate":"2022-06-30"},{"nctId":"NCT04292314","phase":"PHASE2,PHASE3","title":"Hydroxy Urea, Omega 3, Nigella Sativa,Honey on Oxidative Stress and Iron Chelation in Pediatric Major Thalassemia","status":"COMPLETED","sponsor":"Beni-Suef University","startDate":"2019-11-01","conditions":["Iron Overload","Oxidative Stress","Thalassemia Major"],"enrollment":350,"completionDate":"2021-01-20"},{"nctId":"NCT03510715","phase":"PHASE3","title":"An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-08-31","conditions":["Hypercholesterolemia"],"enrollment":18,"completionDate":"2020-02-17"},{"nctId":"NCT04140201","phase":"PHASE4","title":"Effect of Lipid Lowering Agents on Diabetic Retinopathy and Cardiovascular Risk of Diabetic Patients","status":"UNKNOWN","sponsor":"Alaa Hassan ElBaz","startDate":"2020-02","conditions":["Diabetic Retinopathy"],"enrollment":80,"completionDate":"2020-08"},{"nctId":"NCT02890992","phase":"PHASE2","title":"An 8-Week Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-09-15","conditions":["Hypercholesterolaemia"],"enrollment":42,"completionDate":"2019-02-22"},{"nctId":"NCT01399827","phase":"PHASE2","title":"Omega-3 Fatty Acid Supplementation to ADHD Pharmacotherapy in ADHD Adults With Deficient Emotional Self-Regulation Traits","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2012-02","conditions":["Attention Deficit Hyperactivity Disorder (ADHD)","Deficient Emotional Self-Regulation (DESR)"],"enrollment":2,"completionDate":"2017-11"},{"nctId":"NCT02354976","phase":"PHASE2","title":"A Double-blind Randomized Placebo-controlled Study Comparing Epanova and Fenofibrate on Liver Fat in Overweight Subjects.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-09-01","conditions":["Non-alcoholic Fatty Liver Disease (NAFLD","Hypertriglyceridemia"],"enrollment":78,"completionDate":"2016-05-26"},{"nctId":"NCT03574142","phase":"PHASE1","title":"A Ph 1 Study of Epanova® in Healthy Chineses","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2018-06-04","conditions":["Healthy Subjects"],"enrollment":14,"completionDate":"2018-06-27"},{"nctId":"NCT01381354","phase":"PHASE1","title":"Nutrition, Neuromuscular Electrical Stimulation (NMES) and Secondary Progressive Multiple Sclerosis (SPMS)","status":"COMPLETED","sponsor":"University of Iowa","startDate":"2010-10","conditions":["Multiple Sclerosis"],"enrollment":38,"completionDate":"2016-05"},{"nctId":"NCT02642159","phase":"PHASE4","title":"Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-03-15","conditions":["Dyslipidemia"],"enrollment":413,"completionDate":"2017-05-15"},{"nctId":"NCT00090402","phase":"PHASE1,PHASE2","title":"Fish Oil and Alpha Lipoic Acid in Treating Alzheimer's Disease","status":"COMPLETED","sponsor":"Oregon Health and Science University","startDate":"2004-04","conditions":["Alzheimer's Disease","Oxidative Stress","Dementia","Hyperlipidemia","Inflammation"],"enrollment":39,"completionDate":"2007-08"},{"nctId":"NCT02204410","phase":"PHASE4","title":"Omega-3 Supplementation to ADHD Medication in Children","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2014-07","conditions":["Attention Deficit Hyperactivity Disorder","Deficient Emotional Self-Regulation"],"enrollment":21,"completionDate":"2016-08"},{"nctId":"NCT02133664","phase":"PHASE1,PHASE2","title":"Lipoic Acid and Omega-3 Fatty Acids for Cognitive Impairment in Multiple Sclerosis","status":"COMPLETED","sponsor":"Oregon Health and Science University","startDate":"2014-06","conditions":["Multiple Sclerosis","Cognition"],"enrollment":54,"completionDate":"2016-05"},{"nctId":"NCT02359045","phase":"PHASE1","title":"Study in Healthy Subjects to Compare the Concentrations of the Omega-3 Fatty Acids EPA and DHA in Blood When Delivered as Three New Capsules in Relation to the Epanova® Capsule Under Fasting and Fed Conditions","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-02-12","conditions":["Relative Bioavailability","AUC","Cmax","Pharmacokinetics"],"enrollment":137,"completionDate":"2015-07-27"},{"nctId":"NCT01058941","phase":"PHASE1,PHASE2","title":"Lipoic Acid and Omega-3 Fatty Acids for Alzheimer's Disease","status":"COMPLETED","sponsor":"Oregon Health and Science University","startDate":"2010-09","conditions":["Alzheimer's Disease"],"enrollment":67,"completionDate":"2014-12"},{"nctId":"NCT01780974","phase":"PHASE1,PHASE2","title":"Pilot Study: Lipoic Acid and Omega-3 Fatty Acids for Alzheimer's Prevention","status":"COMPLETED","sponsor":"Oregon Health and Science University","startDate":"2013-04","conditions":["Treated Hypertension"],"enrollment":42,"completionDate":"2015-10"},{"nctId":"NCT02279407","phase":"PHASE2","title":"A Study to Investigate Effects of Omega-3 Carboxylic Acids and Dapagliflozin on Liver Fat Content in Diabetic Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-01","conditions":["T2 Diabetes and Fatty Liver Disease (Non-alcoholic Origin)"],"enrollment":223,"completionDate":"2015-12"},{"nctId":"NCT02370537","phase":"PHASE2","title":"A Study to Investigate How Common Pancreatic Exocrine Insufficiency (PEI) is in Patients With Type 2 Diabetes and Also to Investigate the Uptake of a Single Dose of EPANOVA® or OMACOR® in Patients With Different Degrees of PEI","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-03","conditions":["Diabetes Mellitus, Type 2","Exocrine Pancreatic Insufficiency"],"enrollment":490,"completionDate":"2015-11"},{"nctId":"NCT02859129","phase":"PHASE1","title":"Study to Evaluate the 2-Way Interaction Between Multiple Doses of Epanova™ and a Single Dose of Rosuvastatin (Crestor®)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2013-09","conditions":["Hypertriglyceridemia"],"enrollment":114,"completionDate":"2013-11"},{"nctId":"NCT01242527","phase":"PHASE2,PHASE3","title":"Epanova® for Lowering Very High Triglycerides","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2011-01","conditions":["Severe Hypertriglyceridemia"],"enrollment":399,"completionDate":"2012-04"},{"nctId":"NCT02209766","phase":"PHASE1","title":"A Ph1 Study in Healthy Male Japanese and Caucasian After Single and Multiple Doses of D5884(Omega-3-carboxylic Acids)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-08","conditions":["Healthy"],"enrollment":86,"completionDate":"2014-11"},{"nctId":"NCT00000461","phase":"PHASE2","title":"Harvard Atherosclerosis Reversibility Project (HARP)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"1986-12","conditions":["Cardiovascular Diseases","Coronary Disease","Heart Diseases","Myocardial Ischemia"],"enrollment":0,"completionDate":"1992-11"},{"nctId":"NCT01048502","phase":"NA","title":"Fenofibrate and Omega-3 Fatty Acid Modulation of Endotoxemia","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2010-01","conditions":["Cardiovascular Disease"],"enrollment":100,"completionDate":"2011-05"},{"nctId":"NCT01208961","phase":"PHASE2","title":"Epanova® Compared to Lovaza® In a Pharmacokinetic, Single-dose, Evaluation","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-09","conditions":["Severe Hypertriglyceridemia"],"enrollment":54,"completionDate":"2010-11"},{"nctId":"NCT01408303","phase":"PHASE3","title":"[E]PANOVA Combined With a [S]TATIN in [P]ATIENTS With HYPERT[R]IGLYCER[I]DEMIA to Reduce Non-HDL CHOLES[T]EROL","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2011-08","conditions":["Hypertriglyceridemia","Cardiovascular Disease"],"enrollment":646,"completionDate":"2012-06"},{"nctId":"NCT01515839","phase":"NA","title":"Single Photon Emission Computed Tomography (SPECT) Imaging Study of Professional American Football Players","status":"COMPLETED","sponsor":"Amen Clinics, Inc.","startDate":"2009-05","conditions":["Traumatic Brain Injury"],"enrollment":100,"completionDate":"2010-06"},{"nctId":"NCT01391624","phase":"PHASE2,PHASE3","title":"Study on the Possible Effects of Diet Supplementation With Essential Fatty Acids in Chocolate Craving Volunteers","status":"COMPLETED","sponsor":"Federal University of São Paulo","startDate":"2010-08","conditions":["Addictive Behavior","Abstinence Syndrome"],"enrollment":30,"completionDate":"2011-01"},{"nctId":"NCT00891293","phase":"PHASE4","title":"A Second Open-Label Extension of a Double-Blind, Parallel, Phase IV Study to Assess the Efficacy and Safety of Adjunctive Lovaza® (Formerly Known as Omacor®) Therapy in Hypertriglyceridemic Subjects Treated With Antara™","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-03","conditions":["Hypertriglyceridemia"],"enrollment":93,"completionDate":"2008-05"},{"nctId":"NCT00246636","phase":"PHASE4","title":"Evaluation of Efficacy and Safety of Omacor (Omega-3-acid Ethyl Esters) as Add-on Therapy in Hypertriglyceridemic Subjects Treated With Antara (Fenofibrate) Followed by an 8-week Extension","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-10","conditions":["Hypertriglyceridemia"],"enrollment":167,"completionDate":"2007-03"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"_patentsChecked":true,"crossReferences":{"MMSL":"234233","NDDF":"015520","UNII":"F85N2YHE4E","RXNORM":"1652071","UMLSCUI":"C3832882","chemblId":"CHEMBL3137327","ChEMBL_ID":"CHEMBL3137327","DRUGBANK_ID":"DB09568","PUBCHEM_CID":"76322221","MESH_SUPPLEMENTAL_RECORD_UI":"C000708078"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"2014-","companyName":"AstraZeneca","relationship":"Original Developer"},{"period":"present","companyName":"Astrazeneca","relationship":"Current Owner"}],"publicationCount":33,"therapeuticAreas":["Metabolic"],"biosimilarFilings":[],"originalDeveloper":"Astrazeneca Pharms","recentPublications":[{"date":"2025 Sep","pmid":"40731220","title":"The omega effect: Harnessing fish oil for health.","journal":"Atherosclerosis"},{"date":"2023 May","pmid":"36719059","title":"PNPLA3 I148M and response to treatment for hepatic steatosis: A systematic review.","journal":"Liver international : official journal of the International Association for the Study of the Liver"},{"date":"2021 Nov","pmid":"34618982","title":"Omega-3 carboxylic acids and fenofibrate differentially alter plasma lipid mediators in patients with non-alcoholic fatty liver disease.","journal":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology"},{"date":"2021 Dec","pmid":"34431129","title":"Omega-3 fatty acids for the prevention of atherosclerotic cardiovascular disease.","journal":"Pharmacotherapy"},{"date":"2021 Jan 3","pmid":"33392871","title":"Highlights from Studies Presented at the American Heart Association Scientific Session 2020: Navigating New Roads in Prevention.","journal":"Current atherosclerosis reports"}],"companionDiagnostics":[],"genericManufacturers":0,"_genericFilersChecked":true,"genericManufacturerList":[],"status":"approved","companyName":"Astrazeneca","companyId":"astrazeneca","modality":"Small Molecule","firstApprovalDate":"2014","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2014-05-05T00:00:00.000Z","mah":"ASTRAZENECA PHARMS","brand_name_local":null,"application_number":""},{"country_code":"SA","regulator":"SFDA","status":"likely_approved","approval_date":"2014-05-05T00:00:00.000Z","mah":"ASTRAZENECA PHARMS","brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":"2014-05-05T00:00:00.000Z","mah":"ASTRAZENECA PHARMS","brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":"2014-05-05T00:00:00.000Z","mah":"ASTRAZENECA PHARMS","brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":"2014-05-05T00:00:00.000Z","mah":"ASTRAZENECA PHARMS","brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":"2014-05-05T00:00:00.000Z","mah":"ASTRAZENECA PHARMS","brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":2,"withResults":1},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:10:05.091255+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}